FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W348935634> ?p ?o ?g. }

• W348935634 startingPage "107" @default.
• W348935634 abstract "I. Introduction II. THE REGULATORY HISTORY OF BIOLOGICS IN THE UNITED STATES A. The Biologic Control Act of 1902 B. The Pure Food and Drug Act and the Federal Food, Drug, and Cosmetic Act C. The Public Health Service Act D. Natural Source Biological Products and the Hatch-Waxman Act E. The Biologics Price Competition and Innovation Act (BPCIA) III. THE OLD AND NEW PATENT PROVISIONS RELEVANT TO THE BPCIA A. The First-To-Invent Filing System Under the Patent Act of 1952 B. The-First-To-File System Under the AIA C. Provisional Patents D. The Disclosure Requirement IV. THE ROLE OF MARKET EXCLUSIVITY IN PATENTS A. Market Exclusivity in the Biologic Industry B. The Defense for Market Exclusivity V. THE DANGER OF GRANTING MARKET EXCLUSIVITY FOR BIOLOGICS IN A FIRST-TO-INVENT SYSTEM AND THE NEED FOR MODIFICATION OF THE BPCIA A. The Rise of the Biomedical Industry B. Disincentives to Innovation in a Post-AIA Framework 1. Provisional Patent and Disclosure Disincentives 2. Market Exclusivity Disincentives C. Solutions to Protect Innovation in the Biologic Field 1. The Withdrawal of Market Exclusivity Upon Patent Invalidation 2. The Removal of Provisional Patents Biologic Patent Applications VI. CONCLUSION I. INTRODUCTION In the pharmaceutical industry, regulation of biological drugs creates unprecedented challenges to the formulation of innovative patents in the intellectual property field. (1) Revenue once generated by these companies is now threatened by health care reform, increased competition, and government regulation in bringing new drugs to market. (2) Biological drugs are products manufactured from living matter or manufactured in living cells using recombinant DNA biotechnologies. (3) They comprise a wide range of medical products including vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. (4) Biologics are made of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be [from] living entities such as cells and tissues. (5) In the United States, these specialty drugs have become increasingly popular for their ability to treat medical conditions where conventional drugs fail. (6) Although drug sales are predicted to rise by more than four percent in 2014, (7) there still remains a looming threat to break-through innovations in the biomedical industry: the newly enacted Leahy-Smith America Invents Act (AIA). (8) The AIA makes extensive alterations to the U.S. patent framework by attempting to harmonize the U.S. system with international patent law. (9) It does this by changing the U.S. patent filing system a first-to-invent standard to a first-to-file standard. (10) The new filing system provides greater certainty for inventors that their patent will not be invalidated by someone [claiming] an earlier date of invention. (11) However, in the biopharmaceutical context, the AIA puts additional pressure on biomedical companies to patent biological inventions earlier in the research and development (R&D) process. The biotechnological industry is extremely competitive, and drug companies require a large amount of capital to research and develop innovative products. These funds are acquired private investors, who prefer investing in companies with patent protected innovations. Without patent protection, venture capitalists are wary of providing capital because it might become too easy for competitors to undercut the biomedical company's market price with their own similar drugs. (12) Now that the U.S. patent filing system has changed a first-to-invent standard to a first-to-file standard, biopharmaceutical companies will be forced to file provisional applications earlier in the R&D process, or risk pre-emption competing firms, which could deter investors providing capital to the business for future R&D of drugs. …" @default.
• W348935634 created "2016-06-24" @default.
• W348935634 creator A5021973333 @default.
• W348935634 date "2014-01-01" @default.
• W348935634 modified "2023-09-24" @default.
• W348935634 title "The New Era of Biologic Regulation and Patenting Under the America Invents Act" @default.
• W348935634 hasPublicationYear "2014" @default.
• W348935634 type Work @default.
• W348935634 sameAs 348935634 @default.
• W348935634 citedByCount "0" @default.
• W348935634 crossrefType "journal-article" @default.
• W348935634 hasAuthorship W348935634A5021973333 @default.
• W348935634 hasConcept C10138342 @default.
• W348935634 hasConcept C138885662 @default.
• W348935634 hasConcept C144133560 @default.
• W348935634 hasConcept C162324750 @default.
• W348935634 hasConcept C17744445 @default.
• W348935634 hasConcept C18903297 @default.
• W348935634 hasConcept C190253527 @default.
• W348935634 hasConcept C195487862 @default.
• W348935634 hasConcept C199539241 @default.
• W348935634 hasConcept C2778137410 @default.
• W348935634 hasConcept C2779541081 @default.
• W348935634 hasConcept C2984145337 @default.
• W348935634 hasConcept C34974158 @default.
• W348935634 hasConcept C41895202 @default.
• W348935634 hasConcept C86803240 @default.
• W348935634 hasConcept C91306197 @default.
• W348935634 hasConceptScore W348935634C10138342 @default.
• W348935634 hasConceptScore W348935634C138885662 @default.
• W348935634 hasConceptScore W348935634C144133560 @default.
• W348935634 hasConceptScore W348935634C162324750 @default.
• W348935634 hasConceptScore W348935634C17744445 @default.
• W348935634 hasConceptScore W348935634C18903297 @default.
• W348935634 hasConceptScore W348935634C190253527 @default.
• W348935634 hasConceptScore W348935634C195487862 @default.
• W348935634 hasConceptScore W348935634C199539241 @default.
• W348935634 hasConceptScore W348935634C2778137410 @default.
• W348935634 hasConceptScore W348935634C2779541081 @default.
• W348935634 hasConceptScore W348935634C2984145337 @default.
• W348935634 hasConceptScore W348935634C34974158 @default.
• W348935634 hasConceptScore W348935634C41895202 @default.
• W348935634 hasConceptScore W348935634C86803240 @default.
• W348935634 hasConceptScore W348935634C91306197 @default.
• W348935634 hasIssue "1" @default.
• W348935634 hasLocation W3489356341 @default.
• W348935634 hasOpenAccess W348935634 @default.
• W348935634 hasPrimaryLocation W3489356341 @default.
• W348935634 hasRelatedWork W153140254 @default.
• W348935634 hasRelatedWork W1590521976 @default.
• W348935634 hasRelatedWork W1601641343 @default.
• W348935634 hasRelatedWork W166334504 @default.
• W348935634 hasRelatedWork W2042881200 @default.
• W348935634 hasRelatedWork W2091888204 @default.
• W348935634 hasRelatedWork W2187435182 @default.
• W348935634 hasRelatedWork W2265971087 @default.
• W348935634 hasRelatedWork W2266232135 @default.
• W348935634 hasRelatedWork W2269532899 @default.
• W348935634 hasRelatedWork W2337279184 @default.
• W348935634 hasRelatedWork W2389298618 @default.
• W348935634 hasRelatedWork W2528053971 @default.
• W348935634 hasRelatedWork W2559777552 @default.
• W348935634 hasRelatedWork W2607675726 @default.
• W348935634 hasRelatedWork W2734311998 @default.
• W348935634 hasRelatedWork W2992623733 @default.
• W348935634 hasRelatedWork W3031545663 @default.
• W348935634 hasRelatedWork W3122009876 @default.
• W348935634 hasRelatedWork W3213865876 @default.
• W348935634 hasVolume "18" @default.
• W348935634 isParatext "false" @default.
• W348935634 isRetracted "false" @default.
• W348935634 magId "348935634" @default.
• W348935634 workType "article" @default.